| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
108,017 |
54,191 |
$5.01M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
60,270 |
16,305 |
$1.63M |
| 80050 |
General health panel |
9,079 |
7,379 |
$155K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,743 |
1,462 |
$78K |
| 80053 |
Comprehensive metabolic panel |
18,675 |
14,217 |
$78K |
| 86701 |
|
16,810 |
12,912 |
$70K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
18,627 |
14,261 |
$61K |
| 81235 |
|
1,291 |
811 |
$58K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,544 |
2,166 |
$46K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,545 |
2,166 |
$46K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
4,296 |
3,206 |
$46K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,522 |
2,153 |
$45K |
| 86780 |
|
8,184 |
5,836 |
$44K |
| 81001 |
|
20,372 |
15,750 |
$31K |
| 86592 |
|
11,352 |
9,768 |
$27K |
| 80061 |
Lipid panel |
5,582 |
4,304 |
$26K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
6,623 |
4,922 |
$20K |
| 86703 |
|
2,883 |
2,615 |
$18K |
| 84403 |
|
1,553 |
1,185 |
$18K |
| 80074 |
|
2,866 |
1,834 |
$17K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,179 |
3,654 |
$13K |
| 84439 |
|
3,656 |
2,716 |
$12K |
| 82607 |
|
1,571 |
1,230 |
$11K |
| 36415 |
Collection of venous blood by venipuncture |
12,335 |
9,000 |
$10K |
| 81025 |
|
2,926 |
2,368 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
291 |
210 |
$9K |
| 84481 |
|
1,753 |
1,337 |
$8K |
| 82728 |
|
1,845 |
1,371 |
$8K |
| 84270 |
|
721 |
585 |
$7K |
| 82670 |
|
546 |
455 |
$7K |
| 87522 |
Neg quan hep c or qual rna |
567 |
327 |
$6K |
| 84153 |
|
741 |
570 |
$5K |
| 83550 |
|
1,878 |
1,389 |
$5K |
| 83001 |
|
538 |
457 |
$5K |
| 82627 |
|
433 |
365 |
$5K |
| 83002 |
|
508 |
422 |
$5K |
| 87536 |
|
157 |
86 |
$4K |
| 80076 |
|
5,094 |
2,573 |
$4K |
| 83540 |
|
1,843 |
1,407 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,001 |
2,485 |
$3K |
| 83735 |
|
1,107 |
917 |
$3K |
| 84144 |
|
181 |
160 |
$2K |
| 82746 |
|
494 |
326 |
$2K |
| 84146 |
|
178 |
156 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
41 |
31 |
$2K |
| 85651 |
|
1,286 |
1,014 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,583 |
902 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
92 |
78 |
$2K |
| 84550 |
|
1,112 |
881 |
$2K |
| 81003 |
|
3,024 |
2,172 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
178 |
133 |
$2K |
| 82043 |
|
681 |
560 |
$2K |
| 84100 |
|
844 |
685 |
$1K |
| 82570 |
|
661 |
545 |
$1K |
| 86689 |
|
264 |
142 |
$1K |
| 83930 |
|
353 |
305 |
$1K |
| 84702 |
|
191 |
154 |
$932.23 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
55 |
50 |
$892.16 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
66 |
21 |
$440.30 |
| 83970 |
|
30 |
26 |
$430.98 |
| 84480 |
|
360 |
263 |
$427.00 |
| 84156 |
|
193 |
174 |
$258.63 |
| 80164 |
|
42 |
26 |
$241.50 |
| 84436 |
|
343 |
245 |
$223.61 |
| 84478 |
|
1,273 |
645 |
$218.60 |
| 85060 |
|
101 |
87 |
$185.45 |
| 82465 |
|
1,280 |
650 |
$172.79 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
21 |
15 |
$153.39 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
248 |
169 |
$148.16 |
| 84704 |
|
18 |
12 |
$137.30 |
| 85007 |
|
906 |
532 |
$124.57 |
| 84479 |
|
67 |
64 |
$98.31 |
| 86593 |
|
31 |
29 |
$90.19 |
| 82248 |
|
131 |
80 |
$83.74 |
| 84460 |
|
284 |
130 |
$76.91 |
| 84450 |
|
285 |
131 |
$75.04 |
| 82977 |
|
80 |
56 |
$65.28 |
| 84132 |
|
263 |
119 |
$45.24 |
| 82310 |
|
260 |
117 |
$44.58 |
| 86140 |
|
37 |
27 |
$43.75 |
| 82040 |
|
365 |
204 |
$41.75 |
| 86376 |
|
21 |
12 |
$39.72 |
| 82565 |
|
244 |
104 |
$37.16 |
| 82435 |
|
244 |
104 |
$33.36 |
| 82947 |
|
259 |
119 |
$32.45 |
| 82374 |
|
220 |
88 |
$32.32 |
| 84295 |
|
244 |
104 |
$30.24 |
| 84520 |
|
245 |
105 |
$28.68 |
| 85027 |
|
18 |
12 |
$16.23 |
| 84155 |
|
269 |
120 |
$10.53 |
| 84075 |
|
209 |
85 |
$8.72 |
| 82247 |
|
252 |
108 |
$4.96 |
| 80348 |
|
74 |
58 |
$0.00 |
| 80338 |
|
1,766 |
1,099 |
$0.00 |
| 80361 |
|
1,752 |
1,095 |
$0.00 |
| 80373 |
|
1,751 |
1,094 |
$0.00 |
| 80347 |
|
1,688 |
1,045 |
$0.00 |
| 80364 |
|
1,751 |
1,094 |
$0.00 |
| 80370 |
|
1,746 |
1,089 |
$0.00 |
| 80323 |
|
1,063 |
659 |
$0.00 |
| 80336 |
|
1,058 |
653 |
$0.00 |
| 80354 |
|
762 |
513 |
$0.00 |
| 80356 |
|
1,753 |
1,095 |
$0.00 |
| 80337 |
|
1,687 |
1,045 |
$0.00 |
| 80346 |
|
1,064 |
659 |
$0.00 |
| 80369 |
|
912 |
632 |
$0.00 |
| 80365 |
|
64 |
51 |
$0.00 |
| 80372 |
|
64 |
51 |
$0.00 |
| 80362 |
|
981 |
595 |
$0.00 |
| 80325 |
|
74 |
58 |
$0.00 |
| 80360 |
|
64 |
51 |
$0.00 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,293 |
784 |
$0.00 |
| 80377 |
|
15 |
12 |
$0.00 |
| 80353 |
|
2,025 |
1,235 |
$0.00 |
| 80349 |
|
1,760 |
1,095 |
$0.00 |
| 80324 |
|
1,689 |
1,046 |
$0.00 |
| 80376 |
|
596 |
361 |
$0.00 |
| 80359 |
|
1,709 |
1,142 |
$0.00 |
| 80367 |
|
64 |
51 |
$0.00 |
| 99000 |
|
363 |
252 |
$0.00 |
| 80368 |
|
64 |
51 |
$0.00 |
| 80357 |
|
978 |
595 |
$0.00 |
| 80358 |
|
64 |
51 |
$0.00 |
| 80363 |
|
981 |
595 |
$0.00 |